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ABSTRACT  
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
“Is Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray an effective 
adjuvant therapy for Multiple Sclerosis (MS) patients who suffer from central 
neuropathic pain (CNP)?” 
STUDY DESIGN: Systematic review of three randomized controlled trials published 
between 2005-2013, all English language.  
DATA SOURCES: Three randomized controlled studies were obtained using PubMed 
and MedLine.  
OUTCOMES MEASURED: The outcome of each study was the subject’s incidence and 
severity of central neuropathic pain compared to their baseline at the beginning of the 
study. Outcomes were measured using an 11-point pain scale at various intervals. The 
average scores of these participants were used to compare the control group versus the 
intervention group.  
RESULTS: Three randomized controlled trials and uncontrolled, extension trial were 
used in this review. Langford et al demonstrated a mean difference between the 
THC/CBD group and placebo-controlled group to be (odds ratio 1.31 [95% CI, 1.01-2.57 
points]; P=0.046) after 10 weeks. Rog et al found that there was a statistically significant 
mean reduction of pain intensity (Mean change -2.7; 95% CI: -3.4 – 2.0 (p=0.005)) in the 
THC/CBD intervention group. Hoggart et al showed a significant mean reduction in pain 
scores (-0.96 points; 95% CI: -1.59, -0.32, (p=0.004)) when compared to control group. 
All of the results were observed in patients who were already on a stable regimen of 
analgesic medications to treat neuropathic pain related to MS.  
CONCLUSIONS: All three studies demonstrated statistically significant reduction in 
mean central neuropathic pain with THC-CBD oromucosal spray as compared to 
baseline, as well as compared to a placebo-control group. The addition of THC/CBD 
oromucosal spray should be considered in MS patients who suffer from central 
neuropathic pain and do not receive pain relief from standard therapy.  
KEY WORDS: Multiple sclerosis (MS), Tetrahydrocannabinol (THC)/Cannabidiol 
(CBD) oromucosal spray, central neuropathic pain (CNP) 
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INTRODUCTION: 
 
Treating complex medical conditions, such as Multiple Sclerosis (MS), often leads to 
frustration of both the patient and the providers, because current biomedical therapies are 
not adequately treating the pain. There is no known cure for MS, and with current 
treatment regimens, patients are often left unable to perform normal activities of daily 
living. This leads to increased dependence of others, avoidance or interference of certain 
activities, increased difficulty sleeping, fatigue, depression, anxiety, increase use of 
narcotics, and a higher overall perception of pain.1  
MS is an immune-mediated inflammatory disorder of the central nervous system, 
which leads to demyelination, glial scarring, and neuronal loss. 2 It is known to be a 
widely unpredictably disease with four different progression patterns. These include 
Relapsing-Remitting MS (85%), Primary-Progressive MS (10%), Secondary-Progressive 
MS (85%), Progressive-Relapsing MS (5%). Among all these types of MS, central 
neuropathic pain (CNP) is the most common pain syndrome. CNP is characterized by 
constant, extremity pain described as “burning or stabbing,” and up to 32% rate this type 
of pain as “frequent, disabling, and inadequately managed.” 3 It is estimated that 
approximately 63% of all MS patients suffer from central neuropathic pain. 4 
MS remains the most common cause of non-traumatic neurodisability in youth, 
with the average age of onset between 20-40 years old.2 Approximately 400,000 in the 
US and 2.5 million worldwide have MS. There are several risk factors for developing 
MS; including genetics, female gender, Caucasian, residence further from the equator, 
low vitamin D, infection, and smoking. 2 They have identified the genetic marker HLA-
DRb1*1501 haplotype. 3  
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MS ranks 2nd to CHF for the most costly chronic disease.5 When compared to 
their healthy counterparts, MS patients on average are 3.5 times more likely to be 
hospitalized (15.2% vs. 4.3%; p< 0.001), twice more likely to visit the ER (25.5% vs. 
12.2%; p< 0.001) and 2.4 times more likely to require services from either a physical, 
occupational, or speech therapist (23.7% vs. 9.9%; p < 0.001) 5. The average cost for MS 
disease-modifying therapies (DMT) alone range from $8,524 - $54,244, 4 and up to an 
additional $18,829 for other healthcare related costs, per year.5 These economic estimates 
were derived from a systematic review of data from 1998-2008, and do not include some 
of the newer, more costly MS medications.6  
The current accepted treatment regimens for MS includes disease-modifying 
agents such as Interferon Beta 1a and 1b (most common), Glatiramer acetate, 
Mitoxantrone, Natalizumab, Fingolimod, or Teriflunomid. 8 Relapses are often treated 
with high dose methylprednisone, 0.5-1g IV for 5 days. Initial treatment of CNP related 
to MS should be anticonvulsants, such as carbamazepine or gabapentin. Other first line 
agents include tri-cyclic antidepressants, serotonin-noepinepherine reuptake inhibitors, 
and lidocaine 12 hour transdermal patches.8 When 1st line therapy fails, second line 
therapies such as Lamotrigine, buproprion, citalopram, baclofen, tizanidine, and short-
acting opioid therapy may be used.8 In several recent studies, THC/CBD oromucosal 
spray has been shown to decrease neuropathic pain and spasticity, and has recently been 
approved in Canada as an adjuvant therapy for central neuropathic pain in MS.9 This 
systemic review will utilize three randomized control trials and evaluate the effectiveness 
of THC/CBD oromucosal spray on MS related CNP as an adjuvant therapy for patients 
who are currently optimized on other analgesic regimens without resolution of their pain.  
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OBJECTIVE 
The objective of this systematic review is to determine whether or not 
Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray is an effective 
adjuvant therapy for Multiple Sclerosis (MS) patients who suffer from central 
neuropathic pain (CNP)? 
METHODS 
This systematic review of three randomized control trials will investigate a patient 
population greater than 18 years old, who have been previously diagnosed with Multiple 
Sclerosis, and currently optimized analgesic therapy. This study will review three 
THC/CBD oromucosal spray interventions from 5-14 weeks. The comparison group is 
comprised of patients with MS of similar characteristics, all suffering from central 
neuropathic pain, currently optimized on analgesic therapy, and utilizing a visibly 
identical placebo oromucosal spray. Outcomes were measured using an 11-point 
numerical pain scale. Preliminary baseline assessments were made prior to initiation of 
the intervention, and reassessments took place at various intervals throughout each study.  
The key words utilized in the searches were “Multiple sclerosis (MS)”, 
“Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray”, and “central 
neuropathic pain (CNP).” All of the articles were researched by the author were 
published in peer-reviewed journals in the English language, and were found on PubMed 
and the Cochrane library. The articles were selected based off its clinical relevance to the 
question posed by the author. Inclusion criteria for this systemic review included 
publication date after 2005, were over 18 years old, have history of at least 6 months of 
unresolved, central neuropathic pain with evidence on clinical examination, a stable pain 
severity of at least 4 on the numerical pain scale, and had a stable analgesic medication 
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regimen for at least two weeks prior to initiation of the study. Exclusion criteria 
comprised of studies with patients who had severe non-neuropathic pain; psychiatric 
conditions that may alter pain severity such as schizophrenia and psychosis; history of 
substance or alcohol abuse; pregnancy or lactation; diabetes, hypertension, 
cardiovascular, hepatic, renal diseases; or any cannabinoid use at least seven days prior to 
the study were all excluded. The analytics used in this study were mean change from 
baseline, p-values, 95% CI, and NNT. 
Table 1: Demographics and Characteristics of Included Studies  
 
Study Type #Pt Age  
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventions 
Langford1 
(2013) 
Double 
blind 
RCT 
339 48.97 
 +  
10 yrs  
- CNP due to 
MS x 3 months 
with pain of > 
24 last 6 days 
- Therapies must 
be stable x 2 
week prior to 
study 
- Severe pain 
from other 
conditions 
- Psychiatric 
disorder, renal, 
hepatic, CVD, 
or convulsive 
disorder 
- Recent 
cannabis use  
42 THC 2.7mg/CBD 2.5mg 
oromucosal spray PRN. 
Maximum 12 sprays per 
24h.    
Rog2 
(2005) 
Double 
blind 
RCT 
66 48.1  
+  
10 yrs  
-Diagnosed MS 
x 6 months. 
Stable central 
pain x 3 months.  
- Patient’s with 
chronic 
visceral pain, 
on TCA’s or 
have psych 
disorder, 
Current 
cannabis users, 
Pregnant, 
lactating, or on 
levodopa.  
 
2 THC 2.7mg/CBD 2.5mg 
oromucosal spray PRN. 
Self –titrated with 
maximum spray 48 per 
24h 
Serpell3 
(2011) 
Double 
blind 
RCT 
125 54.3  
+  
15 yrs 
>18 y.o., 6 
months of pain, 
baseline pain 
scale 4, stable 
medications x 2 
weeks 
- Cannibis use, 
Psych disorder, 
non-
neuropathic 
pain, Diabetes, 
CVD, HTN, 
cancer, 
terminal ill 
20 THC 2.7mg/CBD 2.5mg 
oromucosal spray PRN 
 
Self-titrated with 
maximum spray 48 per 
24/h 
 
 
OUTCOMES MEASURED 
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The three randomized controlled studies’ outcomes utilized in this study was the average 
perceived pain, described on an 11-point pain numerical rating scale (NRS) score. A 
mean pain score for the experimental group was calculated and compared to baseline 
scores at the beginning of the study. Then the mean pain scores of the experiment group 
were compared to the placebo-controlled group.  
 
RESULTS 
 
Langford et al conducted a randomized, double blind, placebo-controlled, parallel-group 
study, which comprised of 339 patients with MS, and were randomized into an 
interventional group (n= 167) and a placebo-controlled group (n=172).10  Each participant 
was instructed on proper medication delivery during a 1-week baseline period, followed 
by a 14 week treatment phase, where they self-titrated to a maximum of 12 sprays per 24 
hours.10 Participants were required to do daily self-reporting of their CNP using an 11-
point numerical rating pain scale (NPS). At the end of the 14-week treatment phase, all 
participants were invited to begin a open treatment phase (n=58), which consisted of a 2-
week re-titration and 12-week stable dose phase with THC/CBD spray.10 At the end of 
the open trial, participants were entered in a double-blind, randomized withdrawal trial to 
determine the long term efficacy of THC/CBD, and the presence and severity of any side 
effects. 10 
Results of the study determined that there was no significant difference between 
the placebo-controlled and intervention group at baseline. 10 After 10 weeks of treatment, 
there was a statistically significant difference between the intervention and control 
group’s in favor of the THC.CBD spray (odds ratio 1.61 [95% CI: 1.01-2.57]: p= 0.046). 
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10 At the end of the 14-week treatment phase, there was not a statistically significant 
difference between interventional and placebo-controlled group, with a difference of -
0.17 points in favor of THC/CBD spray (odds ratio 1.31 [95% CI: 0.84 – 2.04]: p= 
0.234).10 At the end of the open-trial phase, there was a statistically significant change in 
mean pain scare, with a difference of -0.79 points in favor of THC/CBD spray (90% CI: -
1.37 to – 0.21 points; p=0.028). 10. Statistically significant data was considered in p-
values less than 0.05. 3% of the THC:CBD, and 1% of the placebo groups developed 
sever adverse events (AE) that led to cessation of the treatment, but did not reach a 
statistically significant difference (p = 0.69).10 The most common reported AE was GI 
discomfort. Data was provided by Langford et al, and NNT and NNH (tables 4 and 5) 
were calculated by the author.  
Table 2: Comparison of Control vs. THC/CBD Intervention after 10 and 14 weeks 10 
 10 weeks  14 weeks  
Number of Responders with at 
the 30% improvement level in 
mean CNP NPS 
THC ~ 50% 
Placebo ~ 40% 
THC- 50% 
Placebo- 45% 
 p-value; 95% CI P = 0.046 P = 0.234 
 
Table 3: Comparison of Primary and Secondary Endpoints 10 
 Baseline CNP 
NPS 
14 week CNP NPS from 
baseline  
Randomized- Withdrawal CNP 
NPS from baseline  
Control  
 
6.61 (+/- 1.29) -1.76 (6.61 + 1.29-4.73 + 2.26) -0.03 (6.21 + 1.37) 
THC/CBD 
Intervention 
6.55 (+/- 1.35) -1.93 (6.55 +1.35-4.54 + 2.24) +0.76 (6.49 + 1.31) 
p- value N/A P = 0.47 P= 0.028* 
Mean Change 
in NPS 
+0.06 -0.17 -0.79 
 
Table 4: Numbers needed to treat 10 
Relative risk 
reduction (RRR) 
Absolute risk 
reduction 
Number needed to 
treat (NNT)  
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Table 5: Numbers needed to harm (rate of adverse events) 10 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed to 
harm (NNH) 
EER- CER 
CER 
EER - CER 1/ARI 
0.29 0.02 50 
 
Rog et al., conducted a study evaluating 66 patients with MS CNP and their 
response to THC:CBD oromucosal spray as an adjuvant therapy. In this 5-week, 
randomized, double blind, placebo-controlled, parallel-group study, 64 patients were 
randomized into an interventional group (n=34) and a visually identical placebo group 
(n=32). 11 Each participant underwent a toxicity screening, using up to 4 sprays over 2 
hours. Patients who passed the intoxication screening were entered in a 1-week dosing 
optimization period, where they titrated up to a maximum of 48 sprays in a 24-hour 
period.11 The baseline mean pain score was recorded in the 7 days prior to the 
intoxication screening, using an 11-point pain NRS score.11 During weekly telephone 
follow-ups, patient’s reported pain severity was averaged, then compared to the average 
pain recorded the last week of treatment.  
Results of the study determined that there was no significant difference between 
the placebo-controlled and intervention group at baseline. 11 After the 5 week, the study 
demonstrated a statistically significant difference between the placebo-controlled and the 
interventional group, in favor of the THC:CBD oromucosal spray (-1.25 [95% CI: -2.11 
to -0.39]; p=0.005).11 The study also collected data to determine their numbers needed to 
(ARR) 
EER – CER 
CER 
EER - CER 1/ARR 
0.11 0.05 20 
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treat and numbers needed to harm (tables 7 and 8). During the study 88.2% of CBD:THC 
vs 68.8% of placebo groups developed AE’s. The most common AE’s were dizziness and 
confusion, which did not reach a statistically significant difference (0.19; 95% CI: 0.00-
0.39; p=0.053).11 Statistically significant data was considered in p-values less than 0.05. 
The data in tables 6-8 were provided by Rog et al. 11 
Table 6: Comparison of Control vs. THC:CBD intervention after 5 weeks 11 
 Baseline (95% CI) Primary Endpoint (95% CI) 
Placebo-Controlled 6.37 (5.77- 6.97) 4.96 (4.19 – 5.72) 
THC:CBD Intervention 6.58 (6.00 -7.15) 3.85 (3.13 –4.58) 
p-value   p = 0.005 
 
Table 7: Numbers needed to treat (NNT)11 
Odd’s Ratio: 3 (95% CI: 2.2 to 13) 
 
Table 8: Numbers needed to harm (NNH)11 
 1/ Risk Difference; Odds Ratio; CI; p-value 
At least 1 Adverse Event 1/0.19 = 5   (0.19; CI: 0.00-0.39; p = 0.53) 
 
Serpell et al., conducted a 5 week randomized, double-blind, placebo-controlled 
parallel-group study which evaluated 125 patients with MS CNP, and their response to 
THC:CBD oromucosal spray as an adjuvant therapy. Patients were randomized into the 
THC:CBD intervention group (n=63) and visibly identical placebo-controlled group 
(n=62). 12 Patients entered in a one-week dose optimization period, where they titrated up 
to a maximum of 48 sprays in 24 hours. An average baseline pain NRS score was 
collected in the 7 days prior to the first dosing and was compared to the mean pain score 
of each week, or 3 days prior to withdrawal. 12 
                                                                                    TAXIN, CBD:THC MS PAIN           
 
9
Results of the study determined that there was no significant difference between 
the placebo-controlled group and the intervention group at baseline. 12 After the 5 week 
intervention, the study demonstrated a statistically significant difference between the 
placebo-controlled and the intervention group, in favor of the THC:CBD oromucosal 
spray (-0.96 [95% CI: -1.59 to -0.32] p= 0.004). 12 AE’s reported reached a statistical 
significance difference between the two groups was reported for nausea (THC/CBD 49%  
vs placebo 32%; p= 0.003). The study also collected data to determine the numbers 
needed to treat at 30% and 50%, as well as the numbers needed to harm (tables 10 and 
11). Statistically significant data was considered in p-values less than 0.05. The data in 
tables 9-11 were provided by Serpell et al. 12 
Table 9: Comparison of Control vs. THC:CBD intervention after 5 weeks 12 
 Baseline  (95% CI) Estimated Mean Difference  
(95% CI) 
Placebo-Controlled 7.2 (1.5) - 0.52 (-1.59 to -0.32) 
THC:CBD Intervention 7.3 (1.4) -1.48 (-1.59 to -0.32)  
p-value   p = 0.004 
 
Table 10: Numbers needed to treat (NNT) 12 
NNT (30% pain reduction) 8 patients 
NNT (50% pain reduction) 8 patients  
 
Table 11: Numbers needed to harm (NNH) 12 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed to 
harm (NNH) 
EER- CER 
CER 
EER - CER 1/ARI 
0.90 .10 10 
 
 
DISCUSSION 
In this three-study review was able to show that THC:CBD oromucosal spray is an 
effective adjunctive therapy for MS related CNP.  The Langford, 2013 study failed to 
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meet a statistically significant difference at their primary endpoint, however an 
intermediate endpoint, which more closely represented studys conducted by Rog et al. 
and Serpell et al, (10 weeks vs. 5 weeks), were able demonstrate a statistically significant 
difference in the THC:CBD oromucosal spray, suggesting a stronger placebo response 
after 10 weeks. 10 
These studies also indicated that THC:CBD oromucosal spray is a safe drug to 
use for adjuvant therapy in this population of MS patients with CNP.11 Of those who 
suffered from AE’s, most were considered mild to moderate, and at the completion of the 
study, the majority of AE’s were no longer present. In the Langford 2013 study, a 14 
week open-trial treatment using THC:CBD oromucosal spray, as well as a double blind, 
placebo-controlled 4 week withdrawal trial, was conducted to determine long-term 
efficacy of the spray, and identify any withdrawal symptoms that may present. They 
concluded that THC:CBD oromucosal spray had a statistically significant mean reduction 
in pain and time to treatment failure10  
A limiting factor identified in these studies is a small sample size that was taken 
in the studies (339, 64, 125) 10,11,12 and the results may not accurately reflect the 
population’s response to THC:CBD oromucosal spray therapy.  Studies also indicate a 
strong placebo effect that may have taken place. This may be contributed to the unlimited 
daily dosing for the placebo controlled group in all the studies, versus a maximum daily 
dosage for the THC:CBD oromucosal spray groups.10. Statistical analysis may have also 
been affected by the maximum permitted daily dosage for the THC:CBD oromucosal 
spray which differed between the studies, (24 vs. 48 sprays), and may have altered the 
participant’s perceived analgesic effect.  
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Another limiting factor to consider is the multiple etiologies of “neuropathic pain,” and 
no accepted diagnostic criteria, or bed-side exams that exists to determine if the patient’s 
pain is neuropathic in nature. 13 Some studies accept spasm-related MS pain as 
neuropathic while others do not. 13 Therefore, you could hypothesize that all etiologies of 
MS-related pain could benefit from THC:CBD oromucosal spray.  To enhance 
homogeneity of future study subjects, a standardized, diagnostic criterion should be to 
determined to identify neuropathic pain from other pain etiologies.  
Finally, it is important to note that THC:CBD oromucosal spray is currently in phase III 
clinical trials and is not currently available for purchase in the United States, and thus not 
covered by any US healthcare insurer. 8 Current Federal government regulations make 
marijuana use illegal in all 50 states, however state governments have approved 
medicinal marijuana in 24 states. 8 
CONCLUSION 
This small systematic review was able to determine that the use of THC:CBD 
oromucosal in MS related pain, is an effective adjuvant therapy in patients who are 
currently optimized on pain medication. 10, 11, 12   Future studies should attempt to identify 
diagnostic criteria for neuropathic pain, provide a maximum daily dosage for both the 
THC:CBD oromucosal spray and placebo, and continue to investigate the safety and 
effectiveness of THC:CBD oromucosal spray in MS related pain. Currently there are no 
clinical trials using THC:CBD oromucosal spray on MS related CNP.   
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